Agency - ALS Therapy Development Institute

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that stop ALS as soon as possible.

Description:
Built by and for patients, the Institute is the world's largest ALS research center and the only nonprofit biotechnology company with more than 30 professional scientists focused on a single disease indication. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry.

We envision a future where patients no longer die from ALS and where today's patients are alive, well, and enjoying the company of their children and grandchildren.

We envision a future where treatments are developed for diseases based on their ability to save and improve human lives, not their potential to make profit. In this future we envision a Center where research science is re-connected to patients by bringing together patients, doctors, and researchers to openly share their findings, knowledge, and insight, and where that information is made available to the world. We envision a future where this model has expanded and changed the healthcare system into one that strives and succeeds at effectively seeking treatments for all diseases.

History:
In 1999, after his brother's diagnosis, James Allen Heywood realized that a gap exists in the preclinical development of therapeutics for ALS and founded the ALS Therapy Development Institute (ALS TDI) as an independent research center with a singular focus: develop effective therapeutics that slow and stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). As a 501(c)(3) nonprofit organization, ALS TDI became the world's first nonprofit biotechnology company.

Contact person: Emily Wadsworth, Program Coordinator, (phone), (email)

Address:

215 First Street Cambridge, MA 02142 (See a map)

Web Site: http://www.als.net

Directions:

Nearest Metro/Subway Stop: Kendall Sq Red Line/ Lechmere GreenLine,   Walk distance (in minutes): 5-7 For maps or information, please see http://www.mbta.com

Last updated on May 30, 2012